The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

2009836 citationsJournal Articlebronze Open Access

Authors

Andreas H. Diacon · Stellenbosch University

Alexander S. Pym · South African Medical Research Council

Martin P. Grobusch · National Health Laboratory Service

R. F. Patientia · Stellenbosch University

Roxana Rustomjee · South African Medical Research Council

Liesl Page‐Shipp · Right to Care

Christoffel Pistorius

Abstract

The clinical activity of TMC207 validates ATP synthase as a viable target for the treatment of tuberculosis. (ClinicalTrials.gov number, NCT00449644.)

Topics & Keywords

Tuberculosis Research and Epidemiology Cancer therapeutics and mechanisms Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 360, Issue 23, pp. 2397-2405

DOI: 10.1056/nejmoa0808427

Field-Weighted Citation Impact: 33.61